- Home
- NRXS vs BTAI Comparison
NRXS vs BTAI Comparison
Compare NRXS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- BTAI
- Stock Information
- Founded
- NRXS 2011
- BTAI 2017
- Country
- NRXS United States
- BTAI United States
- Employees
- NRXS N/A
- BTAI N/A
- Industry
- NRXS
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- BTAI Health Care
- Exchange
- NRXS Nasdaq
- BTAI Nasdaq
- Market Cap
- NRXS 17.3M
- BTAI 18.1M
- IPO Year
- NRXS 2023
- BTAI 2018
- Fundamental
- Price
- NRXS $2.85
- BTAI $0.34
- Analyst Decision
- NRXS
- BTAI Buy
- Analyst Count
- NRXS 0
- BTAI 4
- Target Price
- NRXS N/A
- BTAI $2.81
- AVG Volume (30 Days)
- NRXS 30.7K
- BTAI 1.3M
- Earning Date
- NRXS 11-12-2024
- BTAI 03-11-2025
- Dividend Yield
- NRXS N/A
- BTAI N/A
- EPS Growth
- NRXS N/A
- BTAI N/A
- EPS
- NRXS N/A
- BTAI N/A
- Revenue
- NRXS $2,456,219.00
- BTAI $2,276,000.00
- Revenue This Year
- NRXS $383.16
- BTAI $131.23
- Revenue Next Year
- NRXS N/A
- BTAI $45.79
- P/E Ratio
- NRXS N/A
- BTAI N/A
- Revenue Growth
- NRXS N/A
- BTAI 83.25
- 52 Week Low
- NRXS $2.00
- BTAI $0.30
- 52 Week High
- NRXS $3.89
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- NRXS 61.76
- BTAI 42.14
- Support Level
- NRXS $2.48
- BTAI $0.33
- Resistance Level
- NRXS $2.83
- BTAI $0.39
- Average True Range (ATR)
- NRXS 0.26
- BTAI 0.06
- MACD
- NRXS 0.05
- BTAI -0.00
- Stochastic Oscillator
- NRXS 72.86
- BTAI 9.27
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.